Geron Corp Stock Price, News & Analysis

Geron Corporation (NASDAQ: GERN) announced positive results from its IMerge Phase 3 trial of imetelstat in patients with lower risk myelodysplastic syndromes (MDS). The trial met its primary endpoint of 8-week transfusion independence (TI) and a key secondary endpoint at 24 weeks, demonstrating significant benefits compared to placebo. Notably, the median TI duration was nearly one year for 8-week responders and 1.5 years for 24-week responders. No new safety signals were observed, and the company plans for U.S. and EU regulatory submissions in 2023, aiming for a commercial launch in 2024.

Geron Corporation (NASDAQ: GERN) will host a conference call on January 4, 2023, at 8:00 a.m. ET to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat for lower risk myelodysplastic syndromes (MDS). Investors can access the call via a live webcast on Geron’s website. Imetelstat is a first-in-class telomerase inhibitor aimed at treating hematologic malignancies. This trial represents a significant step in evaluating the drug's potential to impact patients' lives.

Geron Corporation (Nasdaq: GERN) announced the grant of non-statutory stock options totaling 867,130 shares to newly hired employees as an inducement for employment. The options were issued on December 21, 2022, at an exercise price of $2.08 per share, matching the stock's closing price on that day. These options include 750,000 shares with a four-year vesting period and 117,130 shares that vest upon achieving specific regulatory milestones. All options comply with Nasdaq rules and the terms of Geron's 2018 Inducement Award Plan.

Geron Corporation (NASDAQ: GERN) reported promising results from the IMerge Phase 2 trial of imetelstat, a telomerase inhibitor for lower risk myelodysplastic syndromes (MDS). The trial showed that 29% of patients achieved durable transfusion independence for over one year, with a median duration of 1.8 years. Additionally, 33% of patients previously treated with luspatercept also reached one-year transfusion independence. There were notable increases in hemoglobin levels and decreases in SF3B1 variant allele frequency correlated with treatment, indicating potential disease modification. Phase 3 results are expected in January 2023.

Geron Corporation (Nasdaq: GERN) granted non-statutory stock options to purchase 566,890 shares of common stock to new employees as an employment inducement. The options, issued at an exercise price of $2.24 per share, equal the closing stock price on the grant date of November 16, 2022. Notably, 470,000 shares vest over four years, while 96,890 shares vest upon achieving specific regulatory milestones. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is part of Geron's 2018 Inducement Award Plan aimed at fostering talent for ongoing clinical trials evaluating its telomerase inhibitor, imetelstat.

Geron Corporation (Nasdaq: GERN) announced that CEO John A. Scarlett will participate in a fireside chat at the Stifel 2022 Healthcare Conference on November 15, 2022, at 10:55 a.m. ET in New York City. The session will be accessible via a webcast on Geron's Investor Relations website, with an archive available for 30 days post-event. Geron is focused on developing treatments for hematologic malignancies, with ongoing Phase 3 trials for its telomerase inhibitor, imetelstat, targeting lower risk myelodysplastic syndromes and relapsed/refractory myelofibrosis.

Geron Corporation (NASDAQ: GERN) announced promising data from its IMerge Phase 2 study on Imetelstat, a telomerase inhibitor, showing over 29% of lower risk MDS patients achieved greater than one-year transfusion independence. The upcoming ASH Annual Meeting will feature multiple abstracts highlighting its efficacy in hematologic malignancies, with Phase 3 IMerge trial top-line results expected in early January 2023. Imetelstat's safety profile is consistent, with reversible adverse effects. The research indicates potential disease-modifying activity, addressing significant needs in blood cancer treatments.

Geron Corporation (Nasdaq: GERN) reported its Q3 2022 financial results, revealing a net loss of $41.1 million ($0.10 per share), up from $26.7 million ($0.08 per share) in Q3 2021. Revenues were $297,000, a significant increase from $109,000 in the same period last year. The company has approximately $195 million in cash, with additional resources expected to fund operations through mid-2024. Top-line results from the IMerge Phase 3 trial on imetelstat are anticipated in January 2023, with a New Drug Application submission planned for 2023. Geron projects total operating expenses for 2022 between $155 million and $165 million.

Geron Corporation (NASDAQ: GERN) will announce its Q3 2022 financial results before the market opens on November 3, 2022. A conference call will be held at 9:00 a.m. ET the same day to discuss these results and key milestones. Participants can access the call via a live webcast or by phone. Geron is focused on developing imetelstat, a first-in-class telomerase inhibitor, currently undergoing two Phase 3 clinical trials for hematologic malignancies.